Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Thomas Flaig and Corbin Eule.
|
|
Connection Strength |
|
|
|
|
|
0.272 |
|
|
|
-
Eule CJ, Flaig TW, Wong K, Graf R, Lam ET. Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations. Prostate Cancer Prostatic Dis. 2023 03; 26(1):188-193.
Score: 0.216
-
Kessler ER, Callihan E, Hu J, Eule C, Srivastava G, Kemme DJ, Iruku P, Rana V, Moore J, Schuster SR, Amirault M, Flaig TW, Lam ET. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma. Cancer Res Commun. 2023 06; 3(6):1004-1012.
Score: 0.056